Survival of Filipino women with breast cancer in the United States.
Filipino
breast cancer
cancer epidemiology
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
18
07
2023
received:
03
12
2022
accepted:
23
07
2023
medline:
23
10
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
The survival of women with early-stage breast cancer varies by racial group. Filipino women with breast cancer are an understudied group and are often combined with other Asian groups. We compared clinical presentations and survival rates for Filipino and White women with breast cancer diagnosed in the United States. We conducted a retrospective cohort study of women with breast cancer diagnosed between 2004 and 2015 in the SEER18 registries database. We compared crude survival between Filipino and White women. We then calculated adjusted hazard ratios (HR) in a propensity-matched design using the Cox proportional hazards model. There were 10,834 Filipino (2.5%) and 414,618 White women (97.5%) with Stage I-IV breast cancer in the SEER database. The mean age at diagnosis was 57.5 years for Filipino women and 60.8 years for White women (p < 0.0001). Filipino women had more high-grade and larger tumors than White women and were more likely to have node-positive disease. Among women with Stage I-IIIC breast cancer, the crude 10-year breast cancer-specific survival rate was 91.0% for Filipino and 88.9% for White women (HR 0.81, 95% CI 0.74-0.88, p < 0.01). In a propensity-matched analysis, the HR was 0.73 (95% CI 0.66-0.81). The survival advantage for Filipino women was present in subgroups defined by age of diagnosis, nodal status, estrogen receptor status, and HER2 receptor status. In the United States, Filipino women often present with more advanced breast cancers than White women, but experience better breast cancer-specific survival.
Sections du résumé
BACKGROUND
The survival of women with early-stage breast cancer varies by racial group. Filipino women with breast cancer are an understudied group and are often combined with other Asian groups. We compared clinical presentations and survival rates for Filipino and White women with breast cancer diagnosed in the United States.
METHODS
We conducted a retrospective cohort study of women with breast cancer diagnosed between 2004 and 2015 in the SEER18 registries database. We compared crude survival between Filipino and White women. We then calculated adjusted hazard ratios (HR) in a propensity-matched design using the Cox proportional hazards model.
RESULTS
There were 10,834 Filipino (2.5%) and 414,618 White women (97.5%) with Stage I-IV breast cancer in the SEER database. The mean age at diagnosis was 57.5 years for Filipino women and 60.8 years for White women (p < 0.0001). Filipino women had more high-grade and larger tumors than White women and were more likely to have node-positive disease. Among women with Stage I-IIIC breast cancer, the crude 10-year breast cancer-specific survival rate was 91.0% for Filipino and 88.9% for White women (HR 0.81, 95% CI 0.74-0.88, p < 0.01). In a propensity-matched analysis, the HR was 0.73 (95% CI 0.66-0.81). The survival advantage for Filipino women was present in subgroups defined by age of diagnosis, nodal status, estrogen receptor status, and HER2 receptor status.
CONCLUSION
In the United States, Filipino women often present with more advanced breast cancers than White women, but experience better breast cancer-specific survival.
Identifiants
pubmed: 37755311
doi: 10.1002/cam4.6403
pmc: PMC10587940
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19921-19934Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
J Natl Cancer Inst. 2022 Jun 13;114(6):792-799
pubmed: 35437573
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Ann Surg Oncol. 2012 Dec;19(13):4085-93
pubmed: 22732838
Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):167-72
pubmed: 19469648
Health Equity. 2020 Jul 02;4(1):292-303
pubmed: 32775939
Cancer. 2005 Dec 15;104(12 Suppl):2895-902
pubmed: 16270313
J Immigr Minor Health. 2017 Dec;19(6):1330-1337
pubmed: 27480158
Oncol Nurs Forum. 2006 Jul 01;33(4):E71-8
pubmed: 16858450
JCO Oncol Pract. 2022 Aug;18(8):e1255-e1264
pubmed: 35594493
Ann Transl Med. 2019 Apr;7(8):179
pubmed: 31168460
Prev Med Rep. 2022 Jul 28;29:101936
pubmed: 35959499
JCO Glob Oncol. 2020 Oct;6:1582-1592
pubmed: 33079607
J Natl Cancer Inst. 2000 Aug 16;92(16):1280-2
pubmed: 10944539
Springerplus. 2016 Jan 26;5:82
pubmed: 26844029
JNCI Cancer Spectr. 2020 Feb 06;4(2):pkaa005
pubmed: 33392441
Am J Health Promot. 2022 Feb;36(2):248-258
pubmed: 34814756
Cancer. 2020 Nov 15;126(22):4957-4966
pubmed: 32954493
Ann Surg Oncol. 2022 Oct;29(11):6729-6730
pubmed: 35913672
BMC Public Health. 2020 Sep 29;20(1):1467
pubmed: 32993596
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
J Clin Oncol. 2019 Aug 1;37(22):1965-1977
pubmed: 31206315
J Racial Ethn Health Disparities. 2022 Dec;9(6):2248-2282
pubmed: 34791615
JAMA. 2013 Jul 24;310(4):389-97
pubmed: 23917289
JAMA Netw Open. 2020 Oct 1;3(10):e2020303
pubmed: 33074325
Sci Rep. 2021 Apr 29;11(1):9247
pubmed: 33927264
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1371-1382
pubmed: 27694108
Womens Health Issues. 2013 Nov-Dec;23(6):e403-10
pubmed: 24183415
J Community Genet. 2019 Apr;10(2):281-289
pubmed: 30259342
J Breast Cancer. 2016 Jun;19(2):112-21
pubmed: 27382386
Cancer. 2022 Mar 01;128(5):1024-1037
pubmed: 34792814
J Immigr Minor Health. 2022 Jun;24(3):639-644
pubmed: 34089445
J Clin Oncol. 2018 Jan 1;36(1):14-24
pubmed: 29035645
Cancer. 2012 Sep 1;118(17):4117-25
pubmed: 22460701
PLoS One. 2019 Oct 24;14(10):e0224064
pubmed: 31647839
J Clin Oncol. 2015 Jul 10;33(20):2254-61
pubmed: 25964252
Cancer Med. 2023 Oct;12(19):19921-19934
pubmed: 37755311
Breast Cancer Res Treat. 2017 Jul;164(1):139-147
pubmed: 28365834
J Immigr Minor Health. 2015 Jun;17(3):729-36
pubmed: 25672992
Cancer. 2019 Sep 15;125(18):3139-3146
pubmed: 31206623
Br J Cancer. 2021 Jan;124(2):315-332
pubmed: 32901135
Ann Surg Oncol. 2023 Sep;30(9):5337-5340
pubmed: 37365415
JAMA Surg. 2023 Jun 1;158(6):592
pubmed: 37043213
Eur J Clin Pharmacol. 2021 Aug;77(8):1095-1111
pubmed: 33515076
Cancer Causes Control. 2016 Jun;27(6):825-9
pubmed: 27106576
J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306
pubmed: 31093668
Nat Commun. 2020 Dec 22;11(1):6433
pubmed: 33353943
Am J Public Health. 2015 Feb;105(2):e98-e109
pubmed: 25521898
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
Ann Surg. 2019 Sep;270(3):484-492
pubmed: 31356281
N Engl J Med. 2021 Feb 4;384(5):474-480
pubmed: 33406325
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Int J Cancer. 2016 May 1;138(9):2136-45
pubmed: 26661680
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1387-1396
pubmed: 33879454
J Natl Cancer Inst. 2021 Apr 6;113(4):390-399
pubmed: 32986828
Breast. 2010 Apr;19(2):109-14
pubmed: 20060295
JAMA Surg. 2023 Jun 1;158(6):583-591
pubmed: 37043210
Health Psychol. 2016 Apr;35(4):407-11
pubmed: 27018733
Prev Chronic Dis. 2019 Feb 14;16:E20
pubmed: 30767860
J Natl Cancer Inst. 2013 Aug 7;105(15):1096-110
pubmed: 23878350
Am J Surg Pathol. 2016 Dec;40(12):e94-e102
pubmed: 27740970
Ann Surg Oncol. 2023 Apr;30(4):2121-2127
pubmed: 36652024
Ann Surg Oncol. 2011 Oct;18(11):3072-8
pubmed: 21847700
Breast Cancer Res Treat. 2011 Jun;127(2):471-8
pubmed: 20957431
BMC Cancer. 2007 Oct 26;7:201
pubmed: 17961259
JAMA Surg. 2018 Jun 1;153(6):588-589
pubmed: 29617544